PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease
BioSpace
PepGen's lead candidate for myotonic dystrophy type 1 barely beat the placebo in a Phase 2 trial in terms of fixing incorrect gene splicing, but the biotech attributed the poor result to an outlier.
pharminent
March 31, 2026 (Last updated: March 31, 2026)
BioSpace
PepGen’s lead candidate for myotonic dystrophy type 1 barely beat the placebo in a Phase 2 trial in terms of fixing incorrect gene splicing, but the biotech attributed the poor result to an outlier.
